Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Surgical Approach with Oncologic Outcomes in Low-Risk Cervical Cancer.

American journal of obstetrics and gynecology·2026
Same author

Comparison of High-Risk Breast Cancer Screenings with Concurrent Versus Staggered Breast MRI and Mammogram Schedules.

Journal of clinical medicine·2026
Same author

Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.

Frontiers in immunology·2026
Same author

Pre-operative positron emission tomography scan is associated with lower rates of adjuvant treatment in surgically treated patients with cervical cancer: a 4C Working Group study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.

Gynecologic oncology·2026
Same author

[Cervical cancer with SHAPE criteria: Conisation before simple hysterectomy].

Bulletin du cancer·2026

Related Experiment Video

Updated: May 30, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.

Xuan Bich Trinh1, Wiebren A A Tjalma, Luc Y Dirix

  • 1Translational Cancer Research Unit, St Augustinus GZA Hospitals, Antwerp, Belgium.

Plos One
|July 30, 2011
PubMed
Summary

Identifying ovarian cancer treatment targets is challenging. This study found that increased activation of specific oncogenic pathways (β-Catenin, E2F1, p63, PI3K, PR, RAS) correlates with better outcomes in advanced serous ovarian tumors.

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Related Experiment Videos

Last Updated: May 30, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
12:42

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression

Published on: August 28, 2012

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Identifying specific therapeutic targets for ovarian cancer remains a significant clinical challenge.
  • Understanding the role of oncogenic pathways is crucial for improving patient outcomes.

Purpose of the Study:

  • To analyze oncogenic pathway activation in ovarian cancer.
  • To investigate the relationship between pathway activation and clinical outcomes in advanced serous ovarian tumors.

Main Methods:

  • A meta-analysis of 6 gene expression datasets was performed.
  • Oncogenic pathway activation scores were analyzed in 464 advanced serous papillary ovarian tumors.
  • Correlations with prognostic signatures (WHR, GGI, IGS) and survival outcomes were assessed.

Main Results:

  • Increased activation of β-Catenin, E2F1, p63, PI3K, PR, and RAS pathways was associated with favorable clinical outcomes.
  • The genomic grade index (GGI), wound healing response (WHR), and invasiveness gene signature (IGS) scores were higher in chemosensitive tumors.
  • PR and RAS pathway activation scores showed significant association with survival.

Conclusions:

  • Specific oncogenic pathway activations (β-Catenin, E2F1, p63, PI3K, PR, RAS) are linked to better clinical outcomes in advanced serous ovarian cancer.
  • The elevated GGI, WHR, and IGS scores in chemosensitive tumors suggest a complex interplay between proliferation and chemosensitivity.
  • Findings highlight potential confounding factors when evaluating prognostic versus predictive biomarkers in ovarian cancer.